tiprankstipranks
Trending News
More News >
Mediwelcome Healthcare Management & Technology Inc. (HK:2159)
:2159
Hong Kong Market

Mediwelcome Healthcare Management & Technology Inc. (2159) AI Stock Analysis

Compare
0 Followers

Top Page

HK

Mediwelcome Healthcare Management & Technology Inc.

(2159)

Rating:55Neutral
Price Target:
HK$0.50
▼(-29.58%Downside)
Mediwelcome Healthcare Management & Technology Inc. faces significant financial challenges, impacting its overall score. Positive technical indicators provide some support, but valuation issues due to negative earnings and a lack of dividend yield limit its appeal. Continued financial and operational improvements are crucial.

Mediwelcome Healthcare Management & Technology Inc. (2159) vs. iShares MSCI Hong Kong ETF (EWH)

Mediwelcome Healthcare Management & Technology Inc. Business Overview & Revenue Model

Company DescriptionMediwelcome Healthcare Management & Technology Inc. (2159) is a company operating within the healthcare sector, primarily focusing on providing comprehensive healthcare management services and technological solutions. The company specializes in offering medical conference services, continuing medical education, and hospital management consulting. By leveraging advanced technology, Mediwelcome aims to enhance healthcare delivery and management efficiency.
How the Company Makes MoneyMediwelcome Healthcare Management & Technology Inc. generates revenue through multiple streams within the healthcare industry. The primary revenue sources include organizing medical conferences and events, which attract healthcare professionals and industry stakeholders, generating income through participation fees and sponsorships. Additionally, the company offers continuing medical education programs, providing valuable training and development for healthcare professionals, thus earning revenue through course fees and partnerships with educational institutions. Mediwelcome also provides hospital management consulting services, assisting healthcare facilities in optimizing their operations and improving patient care, charging fees for their consulting expertise. Strategic partnerships with hospitals, pharmaceutical companies, and educational entities further bolster their revenue streams, allowing the company to expand its service offerings and market reach.

Mediwelcome Healthcare Management & Technology Inc. Financial Statement Overview

Summary
Mediwelcome Healthcare Management & Technology Inc. faces financial challenges with declining revenues and persistent losses. The company's negative cash flows and decreasing equity present significant risks, although there is some cost management improvement and moderate leverage.
Income Statement
45
Neutral
The company's revenue has been declining, with a significant drop from 2021 to 2024. The EBIT and net income margins are negative, indicating operational challenges and losses. However, there is a slight improvement in gross profit margin from 2023 to 2024, suggesting some cost management progress.
Balance Sheet
55
Neutral
The company has maintained positive stockholders' equity, though it has declined over recent years. The debt-to-equity ratio remains moderate, showing some leverage but not excessively risky. The equity ratio is decreasing, indicating lower asset financing through equity, which could pose a risk if liabilities increase.
Cash Flow
40
Negative
The company struggles with cash flow, with negative operating and free cash flows in recent years. The operating cash flow to net income ratio is not meaningful due to negative values, presenting challenges in cash generation. Although there was a significant capital expenditure reduction, it wasn't enough to offset cash flow deficits.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue321.56M331.31M323.37M708.36M432.29M
Gross Profit51.00M29.89M32.55M93.60M96.31M
EBITDA-33.61M-74.53M-69.08M17.72M41.06M
Net Income-45.24M-94.10M-93.74M4.64M21.04M
Balance Sheet
Total Assets194.09M214.32M317.83M366.70M280.08M
Cash, Cash Equivalents and Short-Term Investments71.66M80.35M154.02M174.83M104.89M
Total Debt47.73M31.13M26.48M25.18M25.43M
Total Liabilities120.81M94.35M116.97M73.21M109.08M
Stockholders Equity71.14M116.13M195.02M283.11M161.18M
Cash Flow
Free Cash Flow-27.10M-77.18M-22.75M-24.73M17.31M
Operating Cash Flow-14.05M-75.58M-18.46M262.00K31.12M
Investing Cash Flow-326.00K16.46M-8.36M-16.77M-10.98M
Financing Cash Flow5.68M906.00K54.00K92.84M-4.79M

Mediwelcome Healthcare Management & Technology Inc. Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.71
Price Trends
50DMA
0.56
Positive
100DMA
0.52
Positive
200DMA
0.47
Positive
Market Momentum
MACD
0.08
Positive
RSI
45.08
Neutral
STOCH
43.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2159, the sentiment is Neutral. The current price of 0.71 is above the 20-day moving average (MA) of 0.71, above the 50-day MA of 0.56, and above the 200-day MA of 0.47, indicating a neutral trend. The MACD of 0.08 indicates Positive momentum. The RSI at 45.08 is Neutral, neither overbought nor oversold. The STOCH value of 43.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2159.

Mediwelcome Healthcare Management & Technology Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (57)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
66
Neutral
HK$628.16M19.67-8.91%1.75%169.20%
57
Neutral
£4.68B8.52-61.44%496.52%33.02%4.62%
55
Neutral
HK$142.00M-48.20%-4.57%52.37%
49
Neutral
HK$757.69M
49
Neutral
HK$757.69M
46
Neutral
HK$41.46M-9.43%-3.12%-2869.57%
45
Neutral
HK$5.06B-2.97%11.00%56.87%
44
Neutral
HK$1.36B-18.19%-24.50%-93.44%
44
Neutral
HK$1.36B-18.19%-24.50%-93.44%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:2159
Mediwelcome Healthcare Management & Technology Inc.
0.62
0.26
72.22%
HK:0401
Wanjia Group Holdings Ltd.
0.07
>-0.01
-12.50%
HK:2251
Beijing Airdoc Technology Co. Ltd. Class H
13.02
-1.02
-7.26%
HK:2251
Beijing Airdoc Technology Co. Ltd. Class H
13.02
-1.02
-7.26%
HK:2158
Yidu Tech, Inc.
5.57
1.96
54.29%
HK:2138
EC Healthcare
0.55
-0.62
-52.99%
HK:9686
NEUSOFT XIKANG HOLDINGS INC.
0.90
-0.18
-16.67%
HK:9686
NEUSOFT XIKANG HOLDINGS INC.
0.90
-0.18
-16.67%

Mediwelcome Healthcare Management & Technology Inc. Corporate Events

Mediwelcome Completes HK$16 Million Share Placement
Jul 8, 2025

Mediwelcome Healthcare Management & Technology Inc. has successfully completed the placement of 40 million new shares, raising approximately HK$16 million in gross proceeds. The funds will be used for general working capital, and the placement has slightly altered the company’s shareholding structure without any placee becoming a substantial shareholder.

Mediwelcome Clarifies RSU Scheme Status in 2024 Annual Report
Jul 7, 2025

Mediwelcome Healthcare Management & Technology Inc. has issued a supplemental announcement regarding its 2024 Annual Report, specifically addressing the status of its RSU Scheme. The company clarified that no RSUs were granted or agreed to be granted during 2024, and the number of unvested RSUs for employees remained at zero throughout the year. This announcement does not affect other information in the 2024 Annual Report, indicating stability in the company’s reporting and operations.

Mediwelcome Healthcare Successfully Passes AGM Resolutions
Jun 25, 2025

Mediwelcome Healthcare Management & Technology Inc. announced the successful passing of all proposed resolutions at its Annual General Meeting held on June 25, 2025. The resolutions included the re-election of directors, re-appointment of auditors, and granting of mandates for share issuance and repurchase, all of which were unanimously approved by shareholders, indicating strong support for the company’s strategic direction.

Mediwelcome Announces Share Placement to Raise HK$16 Million
Jun 13, 2025

Mediwelcome Healthcare Management & Technology Inc. has announced a placement of new shares under a general mandate, involving up to 40 million shares at a price of HK$0.40 per share. This move is expected to raise approximately HK$16 million in gross proceeds, with net proceeds of around HK$15.45 million intended for general working capital. The placement represents a significant portion of the company’s shares and is offered at a discount to recent trading prices, indicating a strategic effort to bolster financial resources.

Mediwelcome Announces Capital Reduction in Subsidiary
Jun 13, 2025

Mediwelcome Healthcare Management & Technology Inc. announced a capital reduction for one of its subsidiaries, the Target Company, which will see Beijing Medi Healthcare, a group entity, reduce its registered capital by approximately RMB3.1 million, equating to 51% of the Target Company’s existing capital. This move will result in Beijing Medi Healthcare ceasing to hold any interest in the Target Company, leading to the exclusion of the Target Company’s financial results from Mediwelcome’s consolidated financial statements. The capital reduction is deemed a discloseable transaction under Hong Kong’s listing rules, and the consideration for the reduction was set at RMB7.0 million, based on an independent valuation reflecting market conditions.

Mediwelcome Announces Annual General Meeting with Key Resolutions
Apr 25, 2025

Mediwelcome Healthcare Management & Technology Inc. has announced its upcoming annual general meeting scheduled for June 25, 2025, in Beijing. The meeting will address several key resolutions, including the re-election of directors, the re-appointment of the company’s auditor, and the approval of a general mandate for the directors to issue additional shares. These resolutions are aimed at strengthening the company’s governance and operational capabilities, potentially impacting its market position and shareholder value.

Mediwelcome Enhances Governance with New Nomination Committee
Apr 25, 2025

Mediwelcome Healthcare Management & Technology Inc. has established a Nomination Committee to enhance its corporate governance structure. The committee, primarily composed of independent non-executive directors, is tasked with reviewing the board’s composition and recommending qualified candidates for directorships. This move is expected to strengthen the company’s strategic alignment and ensure diversity and expertise within its leadership.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 08, 2025